Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00418379
Status:
COMPLETED
Last Update Posted:
2016-05-25
First Post:
2007-01-03
Brief Title:
Phase III Study to Assess the Long Term Efficacy Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets
Sponsor:
Stallergenes Greer
Organization:
Stallergenes Greer
Study Overview
Official Title:
A Randomised Double-blind Placebo-controlled Multi-national Multi-centre Phase III Study to Assess the Long Term Efficacy Carry-over Effect and Safety of Two Dosing Regimens of 300 IR Sublingual Immunotherapy SLIT Administered as Allergen-based Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase III study to evaluate Long term efficacy carry-over effect and safety of 300 IR sublingual Immunotherapy SLIT tablets in adults patients suffering from grass pollen rhinoconjunctivitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None